Clinical results of double specific antibody precision therapy for the treatment of specific pancreatic cancer/lung cancer patients

NRG1 gene fusion variation refers to the gene that expresses NRG1 and other genes, resulting in an increase in NRG1 expression levelsThe frequency of NRG1 gene fusion is not high, and it occurs in about 3% of non-small cell lung cancer (NSCLC) patients, and in 1.5% of pancreatic cancer patients, there is less than 1% chance of appearing in other cancer typesHowever, studies have shown that in KRAS wild pancreatic cancer, NRG1 gene fusion recursThis provides a potential target for patients who do not benefit from KRAS inhibitorsMerus developed MCLA-128 is a bispecific antibody capable of binding to both HER2 and HER3 receptorsThe activation of the neuromodulation protein signaling pathway requires HER3 and HER2 to bind to produce an heteropolymer, while MCLA-128 binds to HER2 to prevent it from forming an iso-dipolymer with HER3, thus blocking the signaling of neuromodulating proteins's MCLA-128 mechanism (Photo: Source: Reference s2)Today, researchers at memorial Sloan-Kettering Cancer Center (MSKCC) reported on the performance of three patients who received MCLA-128 treatment through the Expanded Use Program (Expanded Use Program, EAP)These patients have been treated with a variety of therapies, but the disease continues to progressEAP allows them to experiment with innovative therapies that are in the experimental stage with no choiceresults showed that MCLA-128 reduced tumor volume in all three patientsAmong them, a pancreatic cancer patient with tumor diameter decreased by 44% after 8 weeks of treatment, and 54% of the diameter after treatment for 5 months, to meet the standard of partial remissionThe patient has been treated for more than 7 monthspicture source: Reference, the second pancreatic cancer patient in the, the tumor diameter reduced by 25% after 5 months of treatmentHe has been receiving treatment for more than seven months and is still receiving treatmentOne NSCLC patient had a 41% reduction in tumor diameter and improved brain metastasis after five months of treatment The patient has undergone six different pre-treatments, including afatinib He is still receiving treatment "These initial data provide important proof-of-concept for MCLA-128 targeted treatment of tumors that carry the NRG1 gene fusion," said Dr Alison Schram, a medical oncologist at MSKCC The mechanism of action of MCLA-128 is targeted at the molecular level to carry the NRG1 gene fusion tumor, which may be uniquely applicable to targeting this cancer driver References: Retrieved October 28, 2019, from https://ir.merus.nl/news-releases/news-release-details/merus-bispecific-antibody-mcla-128-shows-encouraging-early Retrieved October 28, 2019, from https://ir.merus.nl/static-files/21db931a-51d6-40de-b11f-03b48b78769b Retrieved October 28, 2019, from https://